Risks of phase I research with healthy participants: A systematic review

Clinical Trials : Journal of the Society for Clinical Trials
Rebecca A JohnsonDavid Wendler

Abstract

Tragedies suggest that phase I trials in healthy participants may be highly risky. This possibility raises concern that phase I trials may exploit healthy participants to develop new therapies, making the translation of scientific discoveries ethically worrisome. Yet, few systematic data evaluate this concern. This article systematically reviews the risks of published phase I trials in healthy participants and evaluates trial features associated with increased risks. Data on adverse events and trial characteristics were extracted from all phase I trials published in PubMed, Embase, Cochrane, Scopus, and PsycINFO (1 January 2008-1 October 2012). Inclusion criteria were phase I studies that enrolled healthy participants of any age, provided quantitative adverse event data, and documented the number of participants enrolled. Exclusion criteria included (1) adverse event data not in English, (2) a "challenge" study in which participants were administered a pathogen, and (3) no quantitative information about serious adverse events. Data on the incidence of adverse events, duration of adverse event monitoring, trial agent tested, participant demographics, and trial location were extracted. In 475 trials enrolling 27,185 participants,...Continue Reading

References

May 1, 1986·British Journal of Clinical Pharmacology·J M Royle, E S Snell
May 20, 1998·European Journal of Clinical Pharmacology·M SibilleD V Durand
Feb 9, 2002·Journal of Medical Ethics·J Savulescu, M Spriggs
Apr 16, 2002·The American Journal of Bioethics : AJOB·T Lemmens, C Elliott
Nov 25, 2004·PLoS Medicine·Erick H Turner
Apr 1, 2005·Journal of Medical Ethics·John Harris
May 24, 2005·International Journal of Clinical Pharmacology and Therapeutics·A LutfullinG Wensing
Jul 23, 2005·The American Journal of Bioethics : AJOB·Rosamond Rhodes
May 5, 2006·The New England Journal of Medicine·Robert Steinbrook
May 9, 2006·Nature Biotechnology·Cormac Sheridan
Jun 7, 2006·The American Journal of Bioethics : AJOB·Adil E Shamoo, David B Resnik
Jul 5, 2006·British Journal of Clinical Pharmacology·Michel SibilleEmmanuel Krupka
Apr 6, 2007·Clinical Pharmacology and Therapeutics·N E KassC Flexner
May 18, 2007·JAMA : the Journal of the American Medical Association·Deborah A ZarinDonald A B Lindberg
Oct 5, 2007·The New England Journal of Medicine·Miriam Shuchman
May 30, 2008·The New England Journal of Medicine·Carl Elliott, Roberto Abadie
Feb 20, 2009·PLoS Medicine·Evelyne DecullierFrançois Chapuis
Feb 21, 2009·The New England Journal of Medicine·Alastair J J Wood
Jul 9, 2009·JAMA : the Journal of the American Medical Association·Alec B O'Connor
Nov 11, 2009·PLoS Medicine·Joseph S RossHarlan M Krumholz
Feb 5, 2010·Clinical Pharmacology and Therapeutics·J A DiMasiA Wilson
Mar 30, 2010·Journal of Pain & Palliative Care Pharmacotherapy· U S Food And Drug Administration
Aug 4, 2010·Annals of Internal Medicine·Florence T BourgeoisKenneth D Mandl
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Mar 9, 2012·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Kenan Isen
Oct 18, 2012·The American Journal of Bioethics : AJOB·Charles Foster, Aisha Y Malik
Jan 11, 2013·BMJ : British Medical Journal·Iain ChalmersFiona Godlee
Jun 28, 2015·BMJ : British Medical Journal·Ezekiel J EmanuelDavid Wendler

❮ Previous
Next ❯

Citations

Dec 30, 2017·Clinical Pharmacology and Therapeutics·Joseph DeGeorgeNigel Greene
Sep 18, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Marci D CottinghamJill A Fisher
Oct 10, 2018·Journal of Empirical Research on Human Research Ethics : JERHRE·Jill A FisherRebecca L Walker
Feb 6, 2017·Nature·Jonathan Kimmelman, Carole Federico
Jul 13, 2019·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Lisa McManusJill A Fisher
Dec 5, 2018·Journal of Translational Medicine·Joyson J KarakunnelShivaani Kummar
Feb 13, 2019·Ethics & Human Research·Jill A Fisher, Rebecca L Walker
Aug 17, 2019·The American Journal of Bioethics : AJOB·Erik Malmqvist
Nov 6, 2020·Clinical Pharmacology and Therapeutics·Ewoud-Jan van HoogdalemMartin Kappler
Feb 6, 2021·The American Journal of Bioethics : AJOB·Holly Fernandez LynchEmily A Largent
Nov 15, 2020·European Journal of Clinical Pharmacology·Zejuan WangJin Wang
Jan 23, 2021·Regulatory Toxicology and Pharmacology : RTP·Paul Baldrick, Andreas Reichl
Feb 2, 2021·Clinical Pharmacology and Therapeutics·Manjunath P Pai

❮ Previous
Next ❯

Software Mentioned

STATA
SPSS
COSTART

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved